Seasoned executive brings extensive experience leading corporate legal and governance teams BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid
Total Revenue Increases 10% Year-over-Year for the Fourth Quarter Completes Acquisitions of Parcus Medical and Arthrosurface Company Expects Total Revenue Growth in the 40% to 44% Range for Full Year 2020 BEDFORD, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.
BEDFORD, Mass. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard , a member of the Company’s Board of Directors since August 2018 , has been named interim Chief Executive Officer, effective immediately, while the Board continues
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 6, 2020-- First paragraph, first sentence should read: Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after the close of the market on Thursday, February 20, 2020
BEDFORD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. He was 62.
Accelerates Revenue Growth through Broadened Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities, and Expands Pipeline Conference Call & Webcast January 8 at 8:30 a.m. ET BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 6, 2020-- Anika Therapeutics, Inc.
BEDFORD, Mass. --(BUSINESS WIRE)--Dec. 10, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform , today announced it will commence the full U.S.
BEDFORD, Mass. --(BUSINESS WIRE)--Nov. 15, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform , today announced its participation in two upcoming
